Sinovac Releases Statement on Healive Vaccine Suspension

Tuesday, December 2, 2008 General News J E 4
BEIJING, Dec. 2 Sinovac Biotech Ltd. (NYSE AlternextUS: SVA), a leading provider of vaccines in China, announced today that, theHealth Services Bureau of Fengtai District in the City of Beijing suspendedthe use of 83 doses of inactivated hepatitis A vaccine Healive(R), following areport of the death of a minor in the Fengtai District on November 27, 2008,which coincided with the administration of the vaccine two days prior.

The suspended vaccine was part of lot 2008052105 that passed the routinegovernment inspection in July 2008. To date, 19,850 doses vaccines from thelot have been distributed. According to data released by the Center forAdverse Drug Reaction Monitoring of Beijing, there is no other reportedadverse reaction to the lot to date. Sinovac has not received, and is notaware of, similar notice of suspension from any other district in Beijingwhere the lot has been distributed or any other part of China where other lotsof the Healive(R) vaccine have been distributed. On November 29, 2008, theBeijing Drug Administration and Drug Administration of Haidian District ofCity of Beijing conducted a joint administrative investigation that includedan inspection of the company's manufacturing site and review of itsmanufacturing, inspection and sales processes, and concluded in a writtenreport that no abnormality was found.

Sinovac has full confidence in the quality of its products. It willcontinue to cooperate with government agencies in their investigation of theincident and will provide an update once the investigation is completed.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac'scommercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combinedhepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac iscurrently developing Universal Pandemic Influenza vaccine and Japaneseencephalitis vaccine. Additional information about Sinovac is available onits website, . To be added to our distribution list,please email: more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x871 Fax: +86-10-6296-6910 Email: Investors/Media: Stephanie Carrington / Janine McCargo The Ruth Group Tel: +1-646-536-7017/7033 Email: /

SOURCE Sinovac Biotech Ltd.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Micromet Expands Committed Equity Financing Facili...
LCA-Vision to Present at RBC Capital Markets' 2008...